Highlights Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
17.44 ^USD	+2.05%		+0.06%	+71.15%

02/06	Transcript : Cullinan Therapeutics, Inc. - Special Call
01/06	Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib	01/06	CI
Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases	16/04	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03	CI
North American Morning Briefing : Stock Futures -2-	13/03	DJ
Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines	15/12	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023	03/11	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial	04/23/04	CI
Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors	26/23/26	CI
Cullinan Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Cullinan Oncology Gets FDA Clearance for CLN-617 Study	27/23/27	MT
Cullinan Oncology Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for CLN-617	27/23/27	CI
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting	15/23/15	CI
Cullinan Oncology's Q4 Loss Narrows	09/23/09	MT
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/23/09	CI
Cullinan Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/23/09	CI
Cullinan Oncology to Pay $25 Million for License Agreement With Harbour BioMed	14/23/14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Highlights

Filters